These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7198096)

  • 1. L-Dopa induced jumping behaviour in acutely morphinized mice.
    Pillai NP; Ramaswamy S; Gopalakrishnan V; Ghosh MN
    Indian J Exp Biol; 1981 Sep; 19(9):896-7. PubMed ID: 7198096
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of cholinergic agonists and antagonists on jumping behaviour induced by morphine and L-dopa in mice.
    Pillai NP; Ramaswamy S; Gopalakrishnan V; Ghosh MN
    Indian J Exp Biol; 1984 Jan; 22(1):59-60. PubMed ID: 6746026
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice.
    Kotlinska J; Bochenski M
    Eur J Pharmacol; 2007 Mar; 558(1-3):113-8. PubMed ID: 17222405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
    Fredriksson A; Archer T
    Amino Acids; 2002; 23(1-3):111-32. PubMed ID: 12373526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of jumping behavior by aminophylline in mice treated with threshold doses of amphentamine and dopa.
    Colpaert FC; Lal H
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):587-90. PubMed ID: 4445575
    [No Abstract]   [Full Text] [Related]  

  • 6. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of levodopa and bromocriptine on naloxone-precipitated morphine withdrawal symptoms in mice.
    Samini M; Fakhrian R; Mohagheghi M; Dehpour AR
    Hum Psychopharmacol; 2000 Mar; 15(2):95-101. PubMed ID: 12404338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA.
    Oksman M; Tanila H; Yavich L
    Neuropharmacology; 2009 Mar; 56(3):647-52. PubMed ID: 19084027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment.
    Chen XL; Lu G; Gong YX; Zhao LC; Chen J; Chi ZQ; Yang YM; Chen Z; Li QL; Liu JG
    Cell Res; 2007 Aug; 17(8):689-700. PubMed ID: 17667915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and structural consequences of long-term dietary L-dopa treatment in mice.
    Sahakian BJ; Carlson KR; DeGirolami U; Bhawan J
    Commun Psychopharmacol; 1980; 4(2):169-76. PubMed ID: 7428338
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of withdrawal from L-DOPA compounds on pathochemical changes of motor structures of the brain caused by them].
    Gershteĭn LM; Sergutina AV; Kukuev LA
    Vopr Med Khim; 1994; 40(5):4-8. PubMed ID: 7839669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.
    Visanji NP; Fox SH; Johnston TH; Millan MJ; Brotchie JM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):276-83. PubMed ID: 18955589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased sensitivity to the stimulant effects of morphine conferred by anti-adhesive glycoprotein SPARC in amygdala.
    Ikemoto M; Takita M; Imamura T; Inoue K
    Nat Med; 2000 Aug; 6(8):910-5. PubMed ID: 10932229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors.
    Leal MB; Michelin K; Souza DO; Elisabetsky E
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):781-5. PubMed ID: 12921910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
    J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.